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Background:  Activated  cells  in atherosclerotic  lesions  expose  phosphatidylserine  (PS) on  their  surface.
Annexin  A5  (AnxA5)  binds  to  PS  and  is used  for imaging  atherosclerotic  lesions.  Recently,  AnxA5  was
shown  to inhibit  vascular  inﬂammatory  processes  after  vein  grafting.  Here,  we report  a therapeutic  role  for
AnxA5  in  post-interventional  vascular  remodeling  in a mouse  model  mimicking  percutaneous  coronary
intervention  (PCI).
Methods and  results:  Associations  between  the  rs4833229  (OR  =  1.29  (CI  95%), pallelic =  0.011)  and
rs6830321 (OR  =  1.35  (CI  95%),  pallelic = 0.003)  SNPs  in  the  AnxA5  gene  and  increased  restenosis-
risk  in patients  undergoing  PCI  were  found  in  the GENDER  study.  To  evaluate  AnxA5 effects  on
post-interventional  vascular  remodeling  and  accelerated  atherosclerosis  development  in vivo,  hyper-
cholesterolemic  ApoE−/− mice  underwent  femoral  arterial  cuff  placement  to induce  intimal  thickening.
Dose-dependent  effects  were  investigated  after  3 days  (effects  on  inﬂammation  and  leukocyte  recruit-
ment)  or  14  days  (effects  on  remodeling)  after  cuff  placement.  Systemically  administered  AnxA5  in  doses
of  0.1,  0.3  and  1.0 mg/kg  compared  to  vehicle  reduced  early  leukocyte  and  macrophage  adherence  up
to  48.3%  (p =  0.001)  and  diminished  atherosclerosis  development  by 71.2%  (p  =  0.012)  with  a  reduction
in  macrophage/foam  cell  presence.  Moreover,  it reduced  the  expression  of  the  endoplasmic  reticulum
stress  marker  GRP78/BiP,  indicating  lower  inﬂammatory  activity  of the  cells present.
Conclusions: AnxA5  SNPs  could  serve  as  markers  for restenosis  after  PCI  and  AnxA5  therapeutically  pre-
vents  vascular  remodeling  in  a  dose-dependent  fashion,  together  indicating  clinical  potential  for  AnxA5
against  post-interventional  remodeling.. Introduction
Post-interventional vascular remodeling and accelerated
therosclerosis development are important complications of
evascularization strategies and limit treatment success rate [1].
hese features are elicited by endothelial and atherosclerotic
laque injury, triggering inﬂammatory activation and leukocyte
ecruitment to the injured arterial segment. These cells are the
riving factors behind smooth muscle cell (SMC) proliferation and
xtracellular matrix deposition leading to intimal hyperplasia.
ubendothelial retention and oxidation of low-density lipoprotein
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(LDL) cholesterol is central to the initial lesion formation in both
native atherosclerosis and restenosis development [2,3]. Recently,
it was  postulated that endoplasmic reticulum (ER) stress, leading to
the unfolded protein response (UPR), is involved in the regulation
of inﬂammation in activated vascular cells and the link between
UPR and arterial inﬂammation is emerging as an important factor
in (accelerated) atherosclerosis development [4–7].
AnxA5 is a member of the annexin family of proteins that
calcium-dependently bind to negatively charged phospholipid
surfaces and was originally discovered as an anticoagulant and
antithrombotic protein [8–11] and has been shown to inhibit the
prothrombinase complex [12] and to down-regulate the surface
Open access under the Elsevier OA license.expression of tissue factor [13]. It is now known to have anti-
inﬂammatory and anti-atherosclerotic properties [14,15] and to
regulate interferon  signalling [16]. Viable cells express phos-
phatidylserine (PS) on their inner cellular membrane leaﬂet. When
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Fig. 1. AnxA5 is a genetic risk marker for clinical restenosis after PCI. Association
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cating they are present in a large proportion of the population. Theesults for the allelic test for eight SNPs in the ANXA5 gene (A). LD plot shows that
s4833229 and rs6830321 SNPs are in high LD (r2 = 0.91) (B).
S is externalized, it serves as an ‘eat-me’ signal. Annexin A5
AnxA5) binds reversibly, speciﬁcally and with high afﬁnity to
S [15]. PS becomes externalized during apoptosis, which makes
nxA5 a powerful tool to detect apoptosis (and atherosclerosis)
oth in vitro and in vivo [17]. PS is expressed in native atheroscle-
osis and after revascularisation procedures, and circulating AnxA5
inds with high afﬁnity to these cells, and is therefore present in
igh concentrations in atherosclerotic plaques and injured vascular
egments. PS externalization is normally thought to be associated to
poptosis, but can also be externalized in a controlled and reversible
ay in non-apoptotic cells [18,19].
Plasma levels of AnxA5 are inversely related to the severity of
oronary stenosis and are indicative of the extent of atherosclerotic
laques [20], but are also elevated in subjects with left ventric-
lar hypertrophy and following myocardial infarction [21,22]. It
as recently shown that systemically administered AnxA5 can
revent vein graft disease and vascular inﬂammation [23] and
hat the dimer of annexin A5, diannexin, can protect against renal
schemia–reperfusion injury and inﬂammatory cell inﬁltration
nto transplanted islet grafts [24,25]. Patients with hypercholes-
erolemia and previous coronary heart disease (CHD) undergoing
CI for atherosclerosis are most at risk for inﬂammatory-driven
ost-interventional restenosis development. The risk for devel-
pment of restenosis may  partially be determined by geneticsis 221 (2012) 333– 340
factors. It has been shown that genetic variations in genes encod-
ing inﬂammatory factors (SNPs) can predict the risk for restenosis
after percutaneous coronary intervention (PCI) [26]. The effects of
genetic variation in the AnxA5 gene on clinical restenosis after
PCI or cardiovascular disease progression have thus far not been
elucidated.
In the present study we  investigated the association between
AnxA5 SNPs and restenosis-risk in patients undergoing PCI, fol-
lowed by in vivo evaluation of the therapeutic effectiveness of
AnxA5 in a humanized mouse model for post-interventional vas-
cular remodeling using ApoE3*Leiden mice. Our ﬁndings point to a
potential diagnostic and therapeutic clinical role for AnxA5 against
post-PCI vascular remodeling.
2. Materials and methods
Association between single nucleotide polymorphisms (SNPs)
in the AnxA5 gene, extracted from the GENDER genome wide asso-
ciation study (GWAS) dataset [27] and restenosis-risk following PCI
was investigated.
We  performed in vivo intervention studies in which hyper-
cholesterolemic ApoE−/− mice on a Western-type diet were
subjected to femoral artery cuff placement to induce vascular injury
and remodeling [28]. Cuff placement leads to a localized vascular
inﬂammation, which in turn produces concentric intimal lesions
that can affect vessel patency. The lesions consist of SMCs, connec-
tive tissue and inﬁltrated leukocytes such as macrophages/foam
cells and are strongly inﬂammation-dependent [29]. In these vas-
cular segments, inﬂammatory cell adhesion, inﬁltration, intimal
thickening and lesion composition were assessed using histology,
morphometry and immunohistochemistry (IHC), as described pre-
viously [29]. Treatment with vehicle, 0.1, 0.3 and 1.0 mg/kg AnxA5
was given to operated ApoE−/− mice. A three day protocol was used
to evaluate effects on leukocyte recruitment, and a 14 day proto-
col to evaluate effects on vascular remodeling. All materials and
methods are described in detail in Supplemental material.
3. Results
3.1. Annexin A5 SNP as risk marker for clinical restenosis
AnxA5 plasma levels are linked to the severity of coronary steno-
sis and AnxA5 is a marker of cardiovascular disease progress. These
data indicate a potential role of AnxA5 in (post-interventional)
accelerated atherosclerosis development. Therefore we  investi-
gated the association between AnxA5 SNPs and restenosis risk in
patients undergoing PCI enrolled in the GENDER study, composed
of 866 patients (295 cases that developed restenosis following PCI
and 571 controls that did not develop restenosis). Clinical outcome
was linked to genetic data obtained through a genome-wide asso-
ciation analysis.
The allelic association test identiﬁed two  SNPs, rs4833229 and
rs6830321, which are signiﬁcantly associated with restenosis risk
after PCI (Fig. 1A). Both SNPs increased the risk for resteno-
sis (rs4833229, odds ratio (OR) = 1.29 (95% conﬁdence interval
(CI) 1.06–1.58), pallelic = 0.011 and rs6830321, OR = 1.35 (95% CI
1.10–1.64), pallelic = 0.003), even after adjustment for clinical risk
factors, such as total occlusion, diabetes, smoking and residual
stenosis (Table 1). The minor allele frequencies for cases and
controls from the GENDER population are 0.481 and 0.418 for
rs4833229 and 0.510 and 0.436 for rs6830321 respectively, indi-AnxA5 gene linkage disequilibrium (LD) plot shows that rs4833229
and rs6830321 are in high LD (r2 = 0.91, Fig. 1B). Haplotype analy-
sis in the gene showed similar association results with restenosis
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Table 1
Association between restenosis risk and SNPs in the ANXA5 gene.
SNP Base position Minor/major allele MAF cases/controls OR (95% CI) p Value
rs2306420 122810925 T/C 0.283/0.309 0.88 (0.71–1.10) 0.2622
rs4833229 122820114 A/G 0.481/0.418 1.29 (1.06–1.58) 0.0114
rs1480287 122821231 A/G 0.481/0.215 0.81 (0.63–1.04) 0.0954
rs17449954 122827178 C/T 0.181/0.067 0.86 (0.57–1.30) 0.4705
rs6534309 122829379 C/T 0.058/0.108 0.75 (0.53–1.06) 0.1040
rs6857766 122830735 A/G 0.083/0.230 0.79 (0.62–1.01) 0.0636
rs6830321 122834205 T/C 0.510/0.436 1.35 (1.10–1.64) 0.0034
rs2306416 122837138 CT 0.139/0.145 0.96 (0.72–1.27) 0.7564
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rllelic association results for 8 SNPs included in the annexin A5 gene in the GENDE
llele  frequency. ORs are computed for the minor allele from the two  by two allele co
nd  restenosis-risk with SNPs displaying high linkage.
s found in the single SNP analysis (haplotype ACAGTTGTT, fre-
uency: 0.427, OR = 1.275, p = 0.018). These data link AnxA5 SNPs
o restenosis-risk after PCI and suggest that AnxA5 genotype func-
ions as risk marker for restenosis. We  therefore further explored
nxA5’s therapeutic potential using an in vivo model for restenosis
nd intimal hyperplasia.
.2. Annexin A5 dose-dependently prevents leukocyte
ecruitment after vascular injury
Effects of AnxA5 on leukocyte recruitment to injured arterial
egments was investigated in the femoral artery cuff model in
poE−/− mice receiving daily vehicle or 0.1, 0.3 or 1.0 mg/kg AnxA5
hrough IP injection. Total plasma cholesterol was not affected
y annexin A5 treatment (Supplementary Table I). Three days
fter cuff placement there is inﬂammation in the cuffed arter-
es, with leukocytes both adherent to the endothelial surface and
ith cells that have migrated into the media layer (Fig. 2A). Stain-
ng of arterial lesions at this time point revealed that 0.1, 0.3
nd 1.0 mg/kg/d AnxA5-treated animals displayed a reduced per-
entage of endothelial leukocyte adhesion by 26.7% (p = 0.014),
4.9% (p = 0.010) and 48.3% (p = 0.001) respectively (Fig. 2B). For
onocytes/macrophages, this percentage was reduced by 40.0%
p = 0.029), 66.9% (p = 0.001), and 45.0% (p = 0.037) respectively
Fig. 2C).
The percentage leukocyte inﬁltration into the media was
educed by all AnxA5 treatments by 49.4% (p = 0.008), 53.3%
p = 0.006) and 49.9% (p = 0.011) respectively (Fig. 2D). The per-
entage medial macrophages was reduced by 61.2% (p = 0.025) by
.0 mg/kg AnxA5, the other dosages did not signiﬁcantly affect
onocyte/macrophage extravasation (Fig. 2E). Together, these data
ndicate an important role for AnxA5 in low dosages in the preven-
ion of leukocyte recruitment to injured arterial segments.
.3. Annexin A5 dose-dependently prevents accelerated
therosclerosis development
The inﬂammation caused by cuff placement leads to an inﬂam-
ation driven intimal hyperplasia. Therapeutic effectiveness of
nxA5 on (neo-)intima development was evaluated 14 days after
uff placement. Annexin A5 treatment did not affect plasma total
holesterol concentration (Supplementary Table I). Accelerated
therosclerotic lesion development was measured on sections
tained with HPS and Weigert’s elastin (Fig. 3A). Vehicle-treated
nimals developed intimal thickening, resulting in luminal steno-
is. Quantitative analysis displayed reduced intimal thickening
expressed as m2 per cross-section) after 0.1, 0.3 and 1.0 mg/kg
nxA5-treatment by 54.6% (p = 0.041), 71.2% (p = 0.012) and 66.9%
p = 0.009) respectively (Fig. 3B). Intimal thickening was  38.1% more
educed (p = 0.031) by 0.3 compared to 0.1 mg/kg AnxA5.y. Positions are based on hg18 build. Abbreviations: Chr, chromosome; MAF, minor
ency table. Signiﬁcant association was observed for SNPs rs4833229 and rs6830321
AnxA5 (0.3 and 1.0 mg/kg) also decreased the absolute medial
surface area (m2) by 30.1% (p = 0.012) and 24.1% (p = 0.025, Fig. 3C)
and intima/media ratio by 62.3% (p = 0.004) and 60.3% (p = 0.007,
Fig. 3D), although the lowest dose was ineffective. Furthermore,
luminal stenosis (%) was reduced by 58.0% (p = 0.001) and 58.8%
(p = 0.0004, Fig. 3E), identifying a potent role for AnxA5 in the
control of inﬂammatory post-interventional vascular remodeling.
Compared to 0.1 mg/kg, 0.3 mg/kg AnxA5 had increased protective
effects on both the intima/media ratio (by 38.5%, p = 0.016) and
luminal stenosis percentage (by 33.2%, p = 0.042). The total vessel
wall diameter and luminal areas were both similar in all AnxA5
dosages, except for 1.0 mg/kg, which displayed 27.1% (p = 0.043)
reduced total vessel area (Supplementary Fig. IA and B).
IHC showed profound intravascular macrophages/foam cell
areas, which co-localized with AnxA5 (Supplementary Fig. IIA
and B) staining at both 3d and 14d after surgery. AnxA5 in all
dosages strongly reduced the accumulation of the percentage of
macrophages/foam cell area (Fig. 4A) in the tunica media (Fig. 4B,
p = 0.0002, p = 0.028 and p = 0.0005 respectively) and in the tunica
intima (Fig. 4C, p = 0.002, p = 0.011 and p = 0.002 respectively) after
14d. The 78 kDa glucose regulated protein/BiP (GRP78) is an ER
protein and associates permanently with mutant or defective incor-
rectly folded proteins, preventing their export from the ER lumen.
ER stress including upregulation of GRP78 is present in unsta-
ble atherosclerotic lesions. We investigated if annexin A5 affected
GRP78 expression in cuffed femoral arteries. AnxA5 in all dosages
strongly reduced GRP78 BiP expressing cells in the media (Fig. 4D)
by 50.2% (p = 0.006), 66.3% (p = 0.0006) and 68.0% (p = 0.004) respec-
tively, but not in the intima (Fig. 4E).
4. Discussion
This study demonstrates an important therapeutic role for
AnxA5 in post-interventional intimal hyperplasia and accelerated
atherosclerosis development. Association between AnxA5 SNPs
and increased restenosis-risk in patients undergoing PCI was  found.
Systemic AnxA5 was  effective in preventing intimal thickening
and could dose-dependently reduce leukocyte and macrophage
recruitment to injured arterial segments in ApoE−/− mice in 0.3
and 0.1 mg/kg dosages. Finally, we demonstrate that sustained
therapy reduces accelerated atherosclerosis with fewer inﬁltrated
macrophages/foam cells and UPR-expressing cells in the injured
arterial wall. Together, these date indicate high diagnostic and ther-
apeutic potential for AnxA5 against post-PCI vascular remodeling.
Association between AnxA5 SNPs and restenosis development
were investigated using a large study population that underwent
PCI, the GENDER population. It has already been shown in this
material that mutations in several genes associated with inﬂam-
mation were associated to restenosis development (24). Our results
demonstrate that SNPs rs4833229 and rs6830321 show signiﬁcant
association with increased risk for clinical restenosis (OR 1.29 and
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Fig. 2. Annexin A5 dose-dependently prevents leukocyte recruitment after vascular injury. Representative cross-sections of cuffed-femoral arteries of ApoE−/− mice treated
with  vehicle or 0.1, 0.3 or 1.0 mg/kg/d AnxA5 (leukocyte and macrophage staining, magniﬁcation 80×, arrows indicate positive staining) after 3d (A). Quantiﬁcation of intimal
adhering leukocytes (B) and macrophages (C) as percentage of all cells within the internal elastic lamina and medial inﬁltrated leukocytes (D) and macrophages (E) (%).
Results indicated as mean ± SEM, n = 10. *p < 0.05, **p < 0.01.
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Fig. 3. Annexin A5 reduces accelerated atherosclerosis development in a dose-dependent fashion. Representative cross-sections of cuffed arteries of ApoE−/− mice receiving
vehicle  or 0.1, 0.3 or 1.0 mg/kg AnxA5 (A) after 14d (HPS and Weigert’s elastin staining, magniﬁcation 40×,  arrows indicate internal elastic laminae). Quantiﬁcation of intimal
thickening (m2) (B), medial area (m2) (C), intima/media ratio (D) and luminal stenosis (%) (E). Results indicated as mean ± SEM, n = 10. *p < 0.05, **p < 0.01.
338 M.M. Ewing et al. / Atherosclerosis 221 (2012) 333– 340
Fig. 4. Annexin A5 leads to a less-inﬂammatory phenotype with reduced intravascular signs of ER-stress. Representative cross-sections of cuffed arteries of ApoE−/− mice
receiving vehicle or 0.1, 0.3 or 1.0 mg/kg AnxA5 (A) after 14d (macrophages and GRP78 BiP staining, magniﬁcation 40×,  arrows indicate positive staining) and quantiﬁcation
of  medial (B) and intimal (C) macrophage/foam cell area (%) and medial (D) and intimal (E) GRP78 BiP expression (%). Results indicated as mean ± SEM, n = 10. *p < 0.05,
**p  < 0.01.
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.35, Fig. 1A). This genetic variance in addition to plasma levels [19]
ould allow for excellent stratiﬁcation of patients that are most
t risk for restenosis development, enabling individual tailor-made
reatment strategy. Additionally, our results support the notion that
enetic programming of not only pro-inﬂammatory mediators, but
lso the endogenous anti-inﬂammatory system exerts a signiﬁcant
ole in post-interventional remodeling.
In this study, a perivascular cuff-mediated arterial injury model
as applied, which allows for quick and reproducible lesion for-
ation with continuous blood ﬂow in a patent vessel segment,
lthough the perivascular approach rather differs from clinical
ndovascular injury through balloon inﬂation and stent deploy-
ent during PCI. This perivascular approach could affect the
mount of exposure of subendothelial thrombogenic material and
hrombosis, which are important targets for AnxA5.
Therapeutic effects were shown to most likely result from local
nxA5 binding to activated cells in the injured vascular segment.
ocal AnxA5 can reduce adherence of platelets leukocytes and
ventually prevent their inﬂammatory activation, with reduced
igns of ER-stress and the UPR within these cells. We  found reduced
RP78/BiP expression in the tunica media (Fig. 4D) but not in the
ntima (Fig. 4E) Prolonged intracellular cholesterol storage leads to
ncreased ER stress in cells, which is more likely to occur in foam
ells than in early monocyte/macrophages. In this study, such cells
hould predominantly be found among cells that have migrated
owards the tunica media, which in turn may  explain the differ-
nce between GRP78/BiP expression between the media and intima
ayers.
The fact that clearance of AnxA5 is much slower from the arterial
all than from plasma [30] and accumulates in the injured vascu-
ar wall after systemic injection [23], supports the hypothesis that
nxA5 could act anti-inﬂammatory in levels lower than originally
nvestigated (<1.0 mg/kg). Current results conﬁrm this, with AnxA5
lready effective in reducing leukocyte (Fig. 2B) and macrophage
Fig. 2C) recruitment and intimal thickening (Fig. 3B) in dosages
–10 times lower than previously investigated. This would favour
linical application, where undesired side-effects can be kept to a
inimum.
In conclusion, this study shows that systemic AnxA5 treatment
trongly inﬂuences post-interventional accelerated atherosclerosis
evelopment and can dose-dependently prevent vascular remod-
ling. AnxA5 has previously been successfully applied to diagnose
therosclerotic patients non-invasively [19]. These results there-
ore may  have important clinical implications. Immune-mediated
nterventions directed towards therapeutically controlling the
eukocyte recruitment and vascular remodeling process could
trongly beneﬁt from systemic AnxA5, which could be applied
n an early phase following revascularization or bypass grafting
o prevent accelerated atherosclerosis development. AnxA5 SNPs
ould function as biomarkers in the assessment of restenosis risk
n patients undergoing PCI, improving patient screening. Together,
hese data indicate high clinical potential for AnxA5 against post-
nterventional remodeling.
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